Comparing Intensity Therapeutics (INTS) and The Competition

Intensity Therapeutics (NASDAQ:INTS) is one of 610 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its peers? We will compare Intensity Therapeutics to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, dividends, risk, profitability and valuation.

Profitability

This table compares Intensity Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Intensity Therapeutics Competitors	-809.33%	-698.29%	-27.91%

Analyst Ratings

This is a summary of recent ratings and price targets for Intensity Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1	0	2	1	2.75
Intensity Therapeutics Competitors	8597	13276	40565	1401	2.54

Intensity Therapeutics presently has a consensus price target of $37.50, indicating a potential upside of 894.69%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 66.82%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Intensity Therapeutics is more favorable than its peers.

Risk & Volatility

Intensity Therapeutics has a beta of 2.78, meaning that its share price is 178% more volatile than the S&P 500. Comparatively, Intensity Therapeutics’ peers have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.

Valuation & Earnings

This table compares Intensity Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Intensity Therapeutics	N/A	-$11.61 million	-0.66
Intensity Therapeutics Competitors	$871.41 million	$62.94 million	-28.71

Intensity Therapeutics’ peers have higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 51.4% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 7.1% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 12.2% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Intensity Therapeutics beats its peers on 7 of the 13 factors compared.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.